<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02868385</url>
  </required_header>
  <id_info>
    <org_study_id>RePST</org_study_id>
    <secondary_id>2016-003017-10</secondary_id>
    <nct_id>NCT02868385</nct_id>
  </id_info>
  <brief_title>Repeated Doses of Praziquantel in Schistosomiasis Treatment (RePST)</brief_title>
  <acronym>RePST</acronym>
  <official_title>Repeated Doses of Praziquantel in Schistosomiasis Treatment (RePST): An Open Label, Randomized Controlled Trial of Single vs. Multiple Treatments of Praziquantel in Intestinal African Schistosomiasis in Côte d'Ivoire</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Swiss Tropical &amp; Public Health Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Suisse de Recherches Scientifiques en Côte d'Ivoire</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Leiden University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open label, randomized controlled trial of single vs. multiple treatments of praziquantel
      in intestinal African schistosomiasis in Côte d'Ivoire

      This study aims to determine the efficacy of repeated (up to four times) praziquantel
      treatment against S. mansoni infection in school-age children from Côte d'Ivoire using the
      traditional Kato-Katz thick smear technique, but also with more accurate and non-invasive
      antigen- and DNA-detection methods.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2018</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cure rate</measure>
    <time_frame>8 weeks</time_frame>
    <description>The difference in cure rate (percentage negative) between intervention and control arm by Kato-Katz technique</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction rates</measure>
    <time_frame>8 weeks</time_frame>
    <description>The difference in egg reduction rate (by Kato-Katz), cure rate and circulating anodic and cathodic antigen and DNA reduction rate after multiple doses of praziquantel (40 mg/kg) by Kato Katz (KK), point-of-care circulating cathodic antigen assay (POC-CCA), up-converting phosphor lateral flow circulating anodic antigen assay (UCP-LF-CAA) and polymerase chain reaction (PCR), respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensitivity and specificity</measure>
    <time_frame>8 weeks</time_frame>
    <description>Sensitivity and specificity of Kato Katz (KK), point-of-care circulating cathodic antigen assay (POC-CCA), up-converting phosphor lateral flow circulating anodic antigen assay (UCP-LF-CAA) and polymerase chain reaction (PCR) at different time points.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Schistosomiasis</condition>
  <arm_group>
    <arm_group_label>Control group (A)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1x praziquantel: Children assigned to group A receive a standard single oral dose of praziquantel (40 mg/kg) at baseline (week 0) and will receive no further treatment until the final visit (week 8).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention group (B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4x praziquantel: Children assigned to group B receive a standard single oral dose of praziquantel (40 mg/kg) at baseline (week 0) and will receive three consecutive praziquantel treatments (40 mg/kg) in the following six weeks with 2 weeks intervals.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>4x Praziquantel</intervention_name>
    <description>Five consecutive praziquantel treatments (40 mg/kg): at baseline (week 0) and at week 2, 4, 6, and 8.</description>
    <arm_group_label>Intervention group (B)</arm_group_label>
    <other_name>Biltricide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1x Praziquantel</intervention_name>
    <description>One praziquantel treatment (40 mg/kg) at baseline</description>
    <arm_group_label>Control group (A)</arm_group_label>
    <other_name>Biltricide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject has a confirmed S. mansoni infection (positive POC-CCA test result and at
             least one positive out of triplicate Kato-Katz thick smears)

          -  Subject is aged between 5 and 18 years and otherwise in good health

          -  Subject has received no recent praziquantel treatment in the past month

          -  Subject has provided oral assent and provided written informed consent signed by
             parents/legal guardian

          -  Subject is able and willing to provide multiple stool and urine samples during study

        Exclusion Criteria:

          -  Known allergy to study medication (i.e. praziquantel and albendazole)

          -  Pregnancy

          -  Lactating
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean Coulibaly</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Suisse de Recherches Scientifiques en Côte d'Ivoire</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Govert van Dam</last_name>
    <phone>+31 71 526 44 00</phone>
    <email>g.j.van_dam@lumc.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre Suisse de Recherches Scientifiques en Côte d'Ivoire</name>
      <address>
        <city>Abidjan</city>
        <country>Côte D'Ivoire</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean Coulibaly</last_name>
      <email>couljeanvae@yahoo.fr</email>
    </contact>
    <contact_backup>
      <last_name>Rufin Assaré</last_name>
      <email>hrufinass@yahoo.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Jean Coulibaly</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rufin Assaré</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Côte D'Ivoire</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 9, 2016</study_first_submitted>
  <study_first_submitted_qc>August 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 16, 2016</study_first_posted>
  <last_update_submitted>October 31, 2017</last_update_submitted>
  <last_update_submitted_qc>October 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Leiden University Medical Center</investigator_affiliation>
    <investigator_full_name>Meta Roestenberg</investigator_full_name>
    <investigator_title>MD PhD</investigator_title>
  </responsible_party>
  <keyword>Schistosomiasis</keyword>
  <keyword>Schistosoma mansoni</keyword>
  <keyword>Bilharzia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schistosomiasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Praziquantel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

